Sanuwave Health (NASDAQ:SNWV) Releases Earnings Results, Misses Expectations By $0.03 EPS

Sanuwave Health (NASDAQ:SNWV) issued its earnings results on Tuesday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), FiscalAI reports. The firm had revenue of $9.62 million for the quarter, compared to analysts’ expectations of $9.60 million. Sanuwave Health had a negative return on equity of 299.31% and a net margin of 35.96%.

Sanuwave Health Price Performance

NASDAQ SNWV traded down $0.59 on Thursday, reaching $18.36. 2,341 shares of the stock traded hands, compared to its average volume of 76,020. Sanuwave Health has a 12 month low of $15.35 and a 12 month high of $46.58. The company has a market cap of $157.85 million, a price-to-earnings ratio of 55.61 and a beta of 1.37. The firm’s fifty day simple moving average is $19.06 and its 200 day simple moving average is $25.66. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 10.08.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SNWV. Corient Private Wealth LLC acquired a new stake in Sanuwave Health in the 4th quarter valued at about $257,000. Praetorian PR LLC grew its stake in shares of Sanuwave Health by 1,436.2% in the 4th quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock worth $7,908,000 after purchasing an additional 247,750 shares during the last quarter. Bridgeway Capital Management LLC raised its holdings in shares of Sanuwave Health by 76.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 39,279 shares of the company’s stock worth $1,172,000 after purchasing an additional 17,000 shares in the last quarter. Barclays PLC lifted its stake in Sanuwave Health by 12.7% during the fourth quarter. Barclays PLC now owns 11,610 shares of the company’s stock valued at $346,000 after purchasing an additional 1,306 shares during the last quarter. Finally, Stifel Financial Corp acquired a new stake in Sanuwave Health during the fourth quarter valued at approximately $5,291,000. 42.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SNWV. Wall Street Zen cut Sanuwave Health from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Zacks Research lowered shares of Sanuwave Health from a “hold” rating to a “strong sell” rating in a research note on Monday, March 30th. Roth Mkm reissued a “buy” rating and issued a $47.00 price objective (down from $53.00) on shares of Sanuwave Health in a report on Monday, March 30th. Finally, Weiss Ratings upgraded Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Sanuwave Health currently has a consensus rating of “Moderate Buy” and an average target price of $51.00.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.